Matches in SemOpenAlex for { <https://semopenalex.org/work/W2595067628> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2595067628 abstract "Melanoma brain metastases (MBrM) are devastating, occurring in up to 60% of melanoma patients and are increasing in incidence as systemic treatments improve. MBrM are notoriously difficult to treat and patients suffer from extremely poor survival rates, resulting in these patients being excluded from clinical trials testing new treatments, thus highlighting a need for research in this field.We developed a pre-clinical model where mice have simultaneous intracranial and extracranial B16 melanoma tumours to mimic the clinical setting. Notably, intracranial tumour growth was the survival-limiting factor, allowing the study of therapeutic effects specifically in the brain. Various combinations of anti-PD-1, anti-CTLA-4 and GM-CSF were investigated as potential therapies for MBrM. We found that the combination of anti-PD-1 and anti-CTLA-4 could prolong the survival of these mice; however, this was dependent on the presence of an extracranial tumour.Functional studies revealed that natural killer cells and cytotoxic T-cells were essential mediators of this therapy. Moreover, examination of the infiltrating immune cell populations demonstrated an increase in CD45+ immune cells in the intracranial tumours of mice also bearing a flank tumour and receiving the anti-PD-1 and anti-CTLA-4 therapy. This increase was found to be a result of the increase in infiltrating T-cells and macrophages/microglia and was reliant on the presence of an extracranial tumour.Analysis of cytotoxic T-cells revealed an increase in tumour antigen-specific cells in mice with an intracranial and extracranial tumour receiving treatment. Tumour antigen-specific T-cells within the blood showed an increased expression of homing receptors, which have been previously linked to an increase in T-cell infiltration into the brain.In conclusion, we have demonstrated that the combination of anti-PD-1 and anti-CTLA-4 can be an effective therapy for the treatment MBrM, while also identifying the main immune cell populations involved and a potential mechanism behind the therapeutic efficacy." @default.
- W2595067628 created "2017-03-23" @default.
- W2595067628 creator A5079640864 @default.
- W2595067628 date "2016-10-01" @default.
- W2595067628 modified "2023-09-23" @default.
- W2595067628 title "Cross-talk between the primary tumour and brain metastases enhances the efficacy of immune checkpoint inhibition" @default.
- W2595067628 hasPublicationYear "2016" @default.
- W2595067628 type Work @default.
- W2595067628 sameAs 2595067628 @default.
- W2595067628 citedByCount "0" @default.
- W2595067628 crossrefType "dissertation" @default.
- W2595067628 hasAuthorship W2595067628A5079640864 @default.
- W2595067628 hasConcept C142724271 @default.
- W2595067628 hasConcept C143998085 @default.
- W2595067628 hasConcept C147483822 @default.
- W2595067628 hasConcept C154317977 @default.
- W2595067628 hasConcept C202751555 @default.
- W2595067628 hasConcept C203014093 @default.
- W2595067628 hasConcept C2776914184 @default.
- W2595067628 hasConcept C2777658100 @default.
- W2595067628 hasConcept C2777701055 @default.
- W2595067628 hasConcept C2779830541 @default.
- W2595067628 hasConcept C2780851360 @default.
- W2595067628 hasConcept C502942594 @default.
- W2595067628 hasConcept C55493867 @default.
- W2595067628 hasConcept C71924100 @default.
- W2595067628 hasConcept C86803240 @default.
- W2595067628 hasConcept C8891405 @default.
- W2595067628 hasConceptScore W2595067628C142724271 @default.
- W2595067628 hasConceptScore W2595067628C143998085 @default.
- W2595067628 hasConceptScore W2595067628C147483822 @default.
- W2595067628 hasConceptScore W2595067628C154317977 @default.
- W2595067628 hasConceptScore W2595067628C202751555 @default.
- W2595067628 hasConceptScore W2595067628C203014093 @default.
- W2595067628 hasConceptScore W2595067628C2776914184 @default.
- W2595067628 hasConceptScore W2595067628C2777658100 @default.
- W2595067628 hasConceptScore W2595067628C2777701055 @default.
- W2595067628 hasConceptScore W2595067628C2779830541 @default.
- W2595067628 hasConceptScore W2595067628C2780851360 @default.
- W2595067628 hasConceptScore W2595067628C502942594 @default.
- W2595067628 hasConceptScore W2595067628C55493867 @default.
- W2595067628 hasConceptScore W2595067628C71924100 @default.
- W2595067628 hasConceptScore W2595067628C86803240 @default.
- W2595067628 hasConceptScore W2595067628C8891405 @default.
- W2595067628 hasLocation W25950676281 @default.
- W2595067628 hasOpenAccess W2595067628 @default.
- W2595067628 hasPrimaryLocation W25950676281 @default.
- W2595067628 hasRelatedWork W199925089 @default.
- W2595067628 hasRelatedWork W2013248985 @default.
- W2595067628 hasRelatedWork W2048095498 @default.
- W2595067628 hasRelatedWork W2057042817 @default.
- W2595067628 hasRelatedWork W2563850866 @default.
- W2595067628 hasRelatedWork W2589222165 @default.
- W2595067628 hasRelatedWork W2809064179 @default.
- W2595067628 hasRelatedWork W2810071575 @default.
- W2595067628 hasRelatedWork W287605918 @default.
- W2595067628 hasRelatedWork W2886213129 @default.
- W2595067628 hasRelatedWork W2896289964 @default.
- W2595067628 hasRelatedWork W2901755476 @default.
- W2595067628 hasRelatedWork W2954288760 @default.
- W2595067628 hasRelatedWork W2980394375 @default.
- W2595067628 hasRelatedWork W3013766663 @default.
- W2595067628 hasRelatedWork W3091329595 @default.
- W2595067628 hasRelatedWork W3159111758 @default.
- W2595067628 hasRelatedWork W3209348535 @default.
- W2595067628 hasRelatedWork W560705677 @default.
- W2595067628 hasRelatedWork W77405594 @default.
- W2595067628 isParatext "false" @default.
- W2595067628 isRetracted "false" @default.
- W2595067628 magId "2595067628" @default.
- W2595067628 workType "dissertation" @default.